Federal RuleAug 21
62
DOL Rewrites Disability Rules for 'Merit-Based Opportunity' Push
RuleLabor DepartmentFederal Contract Compliance Programs OfficeSignificant Wallet
HR8083119th CongressWALLET
Allowing Greater Access to Safe and Effective Contraception Act
Sponsored By: Representative Hinson, Ashley [R-IA-2]
Introduced
Summary
Speeds access to routine oral contraceptives. This bill would require the Health and Human Services Secretary to prioritize FDA supplemental reviews for routine oral contraceptives and waive the associated supplemental application fee.
Show full summary
- People 18 and older: Would see faster availability of new or updated oral contraceptives because eligible supplemental applications get priority review and the fee is waived.
- People under 18: Would remain subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act, keeping additional FDA restrictions for minors even after approval.
- Drug manufacturers: Would receive a waiver of the FDA supplemental application fee for qualifying routine oral contraceptives, lowering a barrier to seeking the change.
- Federal oversight and policymakers: The Comptroller General must deliver a Government Accountability Office report within 1 year on 15 years of federal funding for contraceptive methods across Medicare, Medicaid, Indian Health Service, the ACA exchanges, federally qualified health centers, title X, TANF, and TRICARE.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Faster access to routine birth control
This bill would require the HHS Secretary to give priority FDA review to supplemental applications for routine oral birth control pills. The rule would not apply to emergency contraceptives or drugs also approved for induced abortion. The FDA would waive the review fee for any supplemental application receiving priority review. If approved, the product could be available without a prescription for people age 18 or older, while people under 18 would still need a prescription. These rules would apply to applications pending at enactment and to ones submitted after enactment.
Sponsors & CoSponsors
Sponsor
Hinson, Ashley [R-IA-2]
IA • R
Cosponsors
Rep. Miller-Meeks, Mariannette [R-IA-1]
IA • R
Sponsored 3/25/2026
Rep. Nunn, Zachary [R-IA-3]
IA • R
Sponsored 3/25/2026
Rep. Ciscomani, Juan [R-AZ-6]
AZ • R
Sponsored 3/25/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov